Anti-Human VCAM-1

CHO Cell-Derived Recombinant Human VCAM-1 Extracellular Domain

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Blocking: This antibody shows inhibition in the U937 adhesion assay. The adhesion of human U937 cells (5 x 10⁴ cells/well) to 10 μg/ml immobilized rhVCAM-1/Fc (100 μl/well) was maximally inhibited (80 - 100%) following pre-treatment with antibody for 1 hour using 100 μl of a 25 μg/ml antibody solution per well.

Sheep Anti-Human Vascular Cell Adhesion Molecule 1 (VCAM-1) recognizes Human VCAM-1. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

Vascular cell adhesion molecule 1, also known as VCAM1 is an immunoglobulin-like adhesion molecule expressed on activated endothelial cells.¹ This type I membrane protein mediates leukocyte-endothelial cell adhesion and signal transduction, and may play a role in the development of artherosclerosis and rheumatoid arthritis. VCAM-1 promotes the adhesion of lymphocytes, monocytes, eosinophils, and basophils.

1. Huo, Y. et al. (2001) J Clin Invest 107: 1209